<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:hpo ids='HP_0001677'>Coronary artery disease</z:hpo> carries dual risk for atrial tachyarrhythmias and <z:hpo ids='HP_0001645'>sudden cardiac death</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>OBJECTIVE: To examine whether low-dose ranolazine and/or <z:chebi fb="0" ids="50659">dronedarone</z:chebi> can protect against vulnerability to <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> (AF) and ventricular tachyarrhythmias </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: In chloralose-anesthetized, open-chest Yorkshire pigs (n = 15), the proximal segment of left circumflex (LCx) coronary artery was occluded to reduce flow by 75% </plain></SENT>
<SENT sid="3" pm="."><plain>An electrode catheter was positioned on the left atrial appendage to measure AF threshold (AFT) before and during LCx <z:hpo ids='HP_0005145'>coronary artery stenosis</z:hpo> before and at 1 hour after <z:chebi fb="0" ids="50659">dronedarone</z:chebi> (0.5 mg/kg intravenous bolus over 5 minutes) and/or ranolazine administration (0.6 mg/kg intravenous bolus followed by 0.035 mg/kg/min) </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Before drug administration, LCx <z:hpo ids='HP_0005145'>coronary artery stenosis</z:hpo> lowered AFT from 25.2 ± 1.7 mA control (mean ± <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SEM</z:e>) to 4.9 ± 1.0 mA baseline (P&lt;.01) </plain></SENT>
<SENT sid="5" pm="."><plain>At the low doses, neither ranolazine (plasma concentration 2.4 ± 0.6 μM) nor <z:chebi fb="0" ids="50659">dronedarone</z:chebi> (plasma concentration 20.9 ± 3.5 nM) alone blunted the <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced reduction in AFT but were effective together (from 25.2 ± 1.7 mA control to 22.0 ± 3.0 mA during stenosis; P = not significant) </plain></SENT>
<SENT sid="6" pm="."><plain>AF duration (P&lt;.03) and AF inducibility (P = .012) were reduced by ranolazine and <z:chebi fb="0" ids="50659">dronedarone</z:chebi> together but not by either drug alone </plain></SENT>
<SENT sid="7" pm="."><plain>Concurrently, combined but not separate administration blunted the <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced surge in T-wave <z:hpo ids='HP_0001425'>heterogeneity</z:hpo>, a marker of risk for ventricular tachyarrhythmias (from 43.1 ± 11.1 μV control to 149.7 ± 15.1 μV during stenosis, P&lt;.001, compared to 61.7 ± 13.7 μV control to 83.7 ± 15.8 μV during stenosis, P = not significant) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Combined administration of low doses of ranolazine and <z:chebi fb="0" ids="50659">dronedarone</z:chebi> exerts a potent antiarrhythmic action on <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced vulnerability to AF and ventricular tachyarrhythmias due to direct effects on myocardial electrical properties </plain></SENT>
</text></document>